Latest news with #ArgenicaTherapeutics
The Australian
2 days ago
- Health
- The Australian
Health Kick Podcast: Argenica Therapeutics
Stockhead's health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim speaks with Argenica Therapeutics (ASX:AGN) CEO and managing director Dr Liz Dallimore. Did you know that one in four people will suffer a stroke in their lifetime, and only 10% of them will completely recover? In other terms, 15 million people suffer a stroke each year, and 5 million of them will die. They're sobering facts that leave us asking ourselves: What can we do for stroke victims when every second counts? The team at Argenica Therapeutics have been asking themselves the same question for quite some times now, and hopes to improve after-stroke care with its ARG-007 neuroprotective treatment to mitigate brain tissue death. Listen in to hear all the details. This podcast was developed in collaboration with Argenica Therapeutics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
The Australian
6 days ago
- Business
- The Australian
Argenica brain drug paces for FDA clearance
FDA provides clear path for Argenica to lift clinical hold on its ARG-007 stroke drug Further clarification on safety of dose in humans and three additional in vitro lab studies requested Company confident studies are straightforward and can be completed quickly Special Report: Argenica Therapeutics now has a clear path forward to clear the clinical hold currently in place on its investigational new drug application that will enable clinical trials for its lead drug ARG-007. In its full letter, the US Food and Drug Administration (FDA) requested additional information to provide assurance that proposed dosing for a US trial of ARG-007 in acute ischaemic stroke can be achieved safely in humans. The FDA has also requested that Argenica Therapeutics (ASX:AGN) conduct three additional in vitro cell culture studies with clinical research organisations to address identified gaps in data. AGN plans to use safety data from its Phase 2 acute ischaemic stroke trial, which will be available in September, as part of its response to the FDA's request for safety assurance. It adds that three additional studies are small ones that can be completed quickly and build on existing data it has already generated. 'We are pleased to have received the clarification from the FDA as to the additional information required to progress the IND application,' managing director Dr Liz Dallimore said. 'Importantly from a timing and cost perspective, the requested additional in vitro assays are standard assays which are straightforward and efficient to perform. 'Argenica will work with the FDA to ensure the proposed approach to providing the additional information is adequate to lift the clinical hold.' Preventing brain injury During acute neurological events such as stroke, traumatic brain injury (TBI), and hypoxic brain damage, around 1.9 million brain cells die for every minute that blood flow is halted. AGN's ARG-007 is a synthetic peptide designed to protect brain cells from dying in the critical minutes and hours by protecting brain tissue during and after these events. The company noted it was targeting acute ischaemic stroke as many patients that experienced it had a thrombectomy, where a radiologist inserts a catheter through the wrist or groin and guides it up into the brain to physically remove a clot. However, this process has the risk of reperfusion injury, which occurs when blood flow rapidly returns to previously oxygen-deprived brain tissue after a clot is removed and potentially causes additional damage. Dosing of patients in a double-blinded, randomised, placebo-controlled Phase 2 trial of ARG-007 in acute ischaemic stroke patients was completed in April. This involved 92 patients presenting to eight emergency departments around Australia with data-read out due in September with safety the main endpoint. The secondary endpoint for the trial will examine efficacy, with a brain scan taken 48 hours post administration of either the placebo or ARG-007. ARG-007 would be the first neuroprotective drug on the global market if approved, tapping into a large addressable global market for stroke and potentially other indications. The global stroke management market was valued at $36.1 billion in 2022, and is projected to reach $74 bn by 2032, driven by several factors including a growing ageing population. There are more than 45,000 strokes annually in Australia and 795,000 in the US – the world's largest healthcare markets. This article was developed in collaboration with Argenica Therapeutics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Yahoo
05-05-2025
- Business
- Yahoo
ASX Penny Stock Highlights For May 2025
The Australian stock market recently experienced a downturn, with the ASX200 closing down 0.97% at 8,157 points, and sectors like Energy and Financials leading the decline. Despite these broader market challenges, penny stocks continue to capture investor interest due to their potential for significant returns when backed by solid financials. Although the term 'penny stock' might seem outdated, it still highlights smaller or less-established companies that can offer great value; we've identified three such stocks that stand out for their financial strength and potential growth opportunities. Name Share Price Market Cap Financial Health Rating CTI Logistics (ASX:CLX) A$1.75 A$140.95M ★★★★☆☆ Accent Group (ASX:AX1) A$1.865 A$1.06B ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$1.53 A$72.17M ★★★★★★ IVE Group (ASX:IGL) A$2.65 A$408.58M ★★★★★☆ GTN (ASX:GTN) A$0.60 A$114.67M ★★★★★★ West African Resources (ASX:WAF) A$2.28 A$2.6B ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$3.33 A$158.01M ★★★★★★ Regal Partners (ASX:RPL) A$2.15 A$722.75M ★★★★★★ Navigator Global Investments (ASX:NGI) A$1.565 A$766.97M ★★★★★☆ NRW Holdings (ASX:NWH) A$2.67 A$1.22B ★★★★★☆ Click here to see the full list of 990 stocks from our ASX Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Argenica Therapeutics Limited is an Australian biotechnology company focused on the research and development of neuroprotective therapeutic drugs, with a market cap of A$97.99 million. Operations: Argenica Therapeutics generates revenue primarily from the research and development of medical device technology, amounting to A$3.08 million. Market Cap: A$97.99M Argenica Therapeutics, with a market cap of A$97.99 million, is currently pre-revenue and unprofitable, generating limited revenue from research and development activities. The company recently completed dosing for its Phase 2 clinical trial of ARG-007 in acute ischemic stroke patients, with results expected in Q3 2025. Despite having no debt and sufficient cash runway for over two years if current cash flow trends continue, Argenica faces challenges such as negative return on equity and increasing losses over the past five years. Its board lacks extensive tenure experience, which may impact strategic direction. Click here and access our complete financial health analysis report to understand the dynamics of Argenica Therapeutics. Examine Argenica Therapeutics' past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Dusk Group Limited is a retailer in Australia specializing in scented and unscented candles, home decor, home fragrances, and gift solutions with a market cap of A$72.23 million. Operations: The company's revenue primarily comes from retail sales in the home fragrances and accessories segment, amounting to A$136.31 million. Market Cap: A$72.23M Dusk Group, with a market cap of A$72.23 million, reported solid earnings for the half-year ending December 2024, with sales reaching A$87.39 million and net income at A$9.55 million. The company maintains a strong balance sheet with no debt and short-term assets exceeding liabilities by a comfortable margin. Despite trading below its estimated fair value and offering dividends, Dusk faces challenges such as declining profit margins and negative earnings growth over recent years. While the board is experienced, management's short tenure suggests recent changes that could impact strategic execution moving forward. Navigate through the intricacies of Dusk Group with our comprehensive balance sheet health report here. Gain insights into Dusk Group's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Genesis Minerals Limited focuses on the exploration, production, and development of gold deposits in Western Australia, with a market cap of A$4.43 billion. Operations: The company generates revenue of A$561.40 million from its activities in mineral production, exploration, and development. Market Cap: A$4.43B Genesis Minerals Limited has shown significant growth potential, underpinned by its updated Mineral Resources and Ore Reserves estimates, which support the ASPIRE 400 strategy. The company reported a substantial increase in production and sales for the half-year ending December 2024, with net income rising to A$59.8 million. Genesis maintains a strong financial position with more cash than total debt and short-term assets exceeding liabilities. However, its board's relatively short tenure suggests recent changes that could impact strategic direction. Despite trading below estimated fair value, Genesis' low return on equity remains a consideration for investors in penny stocks. Take a closer look at Genesis Minerals' potential here in our financial health report. Explore Genesis Minerals' analyst forecasts in our growth report. Get an in-depth perspective on all 990 ASX Penny Stocks by using our screener here. Ready For A Different Approach? The latest GPUs need a type of rare earth metal called Neodymium and there are only 24 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:AGN ASX:DSK and ASX:GMD. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
06-02-2025
- Business
- Yahoo
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Given this risk, we thought we'd take a look at whether Argenica Therapeutics (ASX:AGN) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. Check out our latest analysis for Argenica Therapeutics A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In June 2024, Argenica Therapeutics had AU$16m in cash, and was debt-free. Looking at the last year, the company burnt through AU$5.1m. Therefore, from June 2024 it had 3.1 years of cash runway. There's no doubt that this is a reassuringly long runway. Depicted below, you can see how its cash holdings have changed over time. Although Argenica Therapeutics reported revenue of AU$2.6m last year, it didn't actually have any revenue from operations. To us, that makes it a pre-revenue company, so we'll look to its cash burn trajectory as an assessment of its cash burn situation. Over the last year its cash burn actually increased by a very significant 53%. While this spending increase is no doubt intended to drive growth, if the trend continues the company's cash runway will shrink very quickly. Argenica Therapeutics makes us a little nervous due to its lack of substantial operating revenue. So we'd generally prefer stocks from this list of stocks that have analysts forecasting growth. While Argenica Therapeutics does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. Argenica Therapeutics has a market capitalisation of AU$91m and burnt through AU$5.1m last year, which is 5.6% of the company's market value. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money. As you can probably tell by now, we're not too worried about Argenica Therapeutics' cash burn. For example, we think its cash runway suggests that the company is on a good path. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. Separately, we looked at different risks affecting the company and spotted 4 warning signs for Argenica Therapeutics (of which 1 doesn't sit too well with us!) you should know about. If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
